Hamps Bio Limited IPO Details
SME
Hamps Bio IPO opens for subscription on 13 Dec 2024 and closes on 17 Dec 2024. The IPO will be listed on BSE with the tentative listing date set for 20 Dec 2024.
Hamps Bio IPO price band has been fixed at ₹51 – ₹51 per share.The face value is ₹10 per share with a lot size of 2000.
Hamps Bio IPO total issue size comprises 12,20,000 shares (aggregating up to ₹6.22 Cr). This includes a fresh issue of 12,20,000 shares (aggregating up to ₹6.22 Cr). Pre-issue shareholding stands at 31,36,000, which will increase to 43,56,000 post-issue.
Hamps Bio IPO carries a ₹60 (117.6%) GMP, reflecting investor sentiment.
Hamps Bio IPO Lot Size : Retain Minimum is 1 lot (2,000 shares) amounting to ₹102,000. Retain Maximum is 1 lot (2,000 shares) amounting to ₹102,000. HNI Minimum is 2 lots (4,000 shares) amounting to ₹204,000.
The Lead Managers for Hamps Bio IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Marwadi Chandarana Intermediaries Brokers Pvt. Ltd.. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is Pure Broking. You can analyze their track record by checking the Market Maker Performance Summary report.
For detailed information, Refer to the Hamps Bio Limited RHP.
Hamps Bio IPO Details
Hamps Bio IPO Subscription
Hamps Bio IPO Application Wise Breakup
Hamps Bio IPO Dates
- 13 Dec 2024Opening dateOPD
- 17 Dec 2024Closing dateCOD
- 18 Dec 2024Allotment Date BOA
- 19 Dec 2024Initiation of RefundsIOR
- 19 Dec 2024Credit of SharesCOS
- 20 Dec 2024Listing dateLID
Hamps Bio IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retain Minimum | 1 | 2000 | ₹102,000 |
| Retain Maximum | 1 | 2000 | ₹102,000 |
| HNI Minimum | 2 | 4000 | ₹204,000 |
Hamps Bio IPO Reservation
Promoter Holding
Documents
Hamps Bio IPO Valuations
Hamps Bio Financial Information
Hamps Bio Limited's revenue increased by 16.41% and profit after tax (PAT) rose by 39.47% between the financial year ending with March 31, 2024 and March 31, 2023.
| Period Ended | 31 Oct 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 644.00 | 514.77 | 395.87 | 364.31 |
| Revenue | 436.42 | 650.13 | 558.49 | 534.46 |
| Profit After Tax | 34.08 | 50.07 | 35.90 | 12.15 |
| Net Worth | 370.78 | 337.42 | 136.30 | 100.57 |
| Reserves and Surplus | 57.18 | 141.42 | -13.70 | -49.43 |
| Total Borrowing | 138.31 | 104.52 | 173.77 | 204.31 |
| Amount in ₹ Lakhs | ||||
About Hamps Bio IPO
Incorporated in 2007, Hamps Bio Limited is engaged in the marketing and distribution of pharmaceutical products like tablets, syrups, capsules, injectables, oil, and nutritional supplements.
The company distributes its products through a network of over 50 distributors and e-commerce platforms, including Amazon (US, Canada, EU), Flipkart, and Jio Mart. Their pharma products are sold in 8 states and union territories, while Freeze-dried and Frozen products reach 6 countries and 22 states and union territories.
The company's business is divided into two segments:
- Pharmaceuticals: The company's pharmaceutical products are marketed under the "Hamps" brand. The range includes tablets, syrups, capsules, injectables, and powders.
- Freeze-dried and Frozen products: The FMCG division focuses on freeze-dried and frozen items under the "FzyEzy" brand. The company operates through both B2B and B2C models, offering products under its brand and through contract manufacturing. Freeze-dried and frozen products include Strawberry, Jamun, Mango, Beet Powder, Chikoo powder etc.
The Company offers over 180 products across both segments. As of October 31, 2024, The Company had 78 employees.
Competitive Strengths:
- Expert Leadership and Industry Experience Driving Strategic Business Growth
- Distribution Network with an Expansive E-Retailing Presence
- Wide and diversified range of products
- Diversified, global customer base with long-standing relationships
- Wide Geographical Presence
- Brand Identity
Strength Of Hamps Bio IPO
1. Expert Leadership and Industry Experience driving Strategic Business Growth.
2. Distribution Network with Expansive E-Retailing Presence.
3. Wide and diversified range of products.
4. Diversified, global customer base with long standing relationships.
5. Wide Geographical Presence.
6. Brand Identity.
7. Quality Assurance.
Risk Of Hamps Bio IPO
1. We have certain outstanding litigation against us, an adverse outcome of which may adversely affect our business, reputation and results of operations.
2. We do not have our own manufacturing facility for pharmaceutical products and we have to rely on third parties for procuring pharmaceutical products sold by our Company.
3. Our existing manufacturing facility for freeze dried and frozen products is concentrated in a single region i.e., Ankelshwar, Gujarat and the inability to operate and grow our business in this particular region may have an adverse effect on our business, financial condition, results of operations, cash flows and future business prospects.
4. We operate in a highly regulated and controlled industry environment. Our Company operates under several statutory and regulatory permits, licenses and approvals. Our failure to obtain and/or renew any approvals or licenses in future may have an adverse impact on our business operations.
5. Our failure to comply with applicable quality standards may result in product liability claims, which could adversely affect our business, financial condition, cash flows and results of operations.
6. The availability of counterfeit drugs, such as those passed off by others as our products, and the introduction of alternative pharmaceutical products due to changes in technology or consumer needs, could adversely affect our goodwill, results of operations, financial results, and business prospects.
7. Any disruptions to the supply, or increases in the pricing, of the raw materials and finished products that we outsource, may adversely affect the supply and pricing of our products and, in turn, adversely affect our business, cash flows, financial condition and results of operations.
8. Our Group Companies has incurred losses in past financial years.
9. Our Company had negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact our growth and business.
10. We are dependent upon few suppliers for the material requirements of our Freeze dried and Frozen Products business. Further, we do not have definitive agreements or fixed terms of trade with most of our suppliers. Failure to successfully leverage our relationships with existing suppliers or to identify new suppliers could adversely affect our business operations.
Objectives Hamps Bio IPO
- Purchase of plant & machinery for FMCG division
- Enhancing the visibility and awareness of the brand
- General corporate purposes
Company Contact Details
Hamps Bio Limited
2900/112,
GIDC, Near Atul Limited,
Ankleshwar, Bharuch 393 002
Phone: +91 8000006663
Email: info@hampsbio.com
Website: http://www.hampsbio.com/
Registrar Contact Details
Lead Mangers
Lead Manager Reports
Market Maker
Market Maker Reports